share_log

HC Wainwright & Co. Reiterates Buy on Summit Therapeutics, Maintains $45 Price Target

HC Wainwright & Co. Reiterates Buy on Summit Therapeutics, Maintains $45 Price Target

HC 温莱特证券重申买入峰会生物科技,维持45美元的目标价
Benzinga ·  10/04 05:30  · 评级/大行评级

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) with a Buy and maintains $45 price target.

HC Wainwright& Co.分析师Mitchell Kapoor重申买入Summit Therapeutics(NASDAQ:SMMT),并维持45美元的目标价格。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发